A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF 07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Axitinib (Primary) ; PF-07265807 (Primary) ; Sasanlimab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Pfizer
- 01 Apr 2024 Planned End Date changed from 20 Feb 2024 to 30 Jun 2024.
- 01 Apr 2024 Planned primary completion date changed from 20 Feb 2024 to 30 Jun 2024.
- 21 Jul 2023 Planned End Date changed from 12 Apr 2024 to 20 Feb 2024.